Scott D. Pegan, Ph.D. Professor, Biomedical Sciences Associate Dean of Pre-Clerkship Medical Education
Photo Credit: Courtesy of University of California, Riverside
Scientific Frontline: Extended "At a Glance" Summary: CCHFV Antibody Therapy
The Core Concept: Researchers have discovered that the internal nucleocapsid protein (NP) of the Crimean-Congo hemorrhagic fever virus (CCHFV) can serve as a viable target for protective antibodies, offering a new pathway for therapeutics against the disease.
Key Distinction/Mechanism: Unlike neutralizing antibodies that target surface proteins to prevent viral entry, these non-neutralizing antibodies target the NP. It is hypothesized they bind to the NP on the surface of infected cells or free-floating NPs, which are then taken inside the cell to interact with the intercellular protein TRIM21, mobilizing the immune system to clear the infection.
Major Frameworks/Components:
- Nucleocapsid Protein (NP): An internal viral protein previously used primarily for diagnostics, now identified as a therapeutic target with four distinct binding areas for antibodies (on its "head" and "stalk").
- Antibody 9D5: A powerful, non-neutralizing mouse antibody that binds to the head region of the NP, protecting against lethal infection and demonstrating broad-spectrum potential.
- TRIM21 Pathway: An intercellular protein mechanism that appears to facilitate the immune system's response when NP-targeting antibodies are internalized.
Branch of Science: Virology, Immunology, and Biomedical Sciences.
Future Application: The findings provide a blueprint for designing new, broad-spectrum human or humanized antibody drugs and cocktail treatments for CCHFV, potentially reaching patients in five years, and suggest NPs could be therapeutic targets for other viruses like the Lassa virus.
Why It Matters: CCHFV is a dangerous, tick-borne virus capable of killing up to 40% of infected individuals. With no currently approved, highly effective treatments or vaccines, and with changing environmental conditions expanding the habitat of its primary vector (Hyalomma ticks), this discovery opens critical new avenues for developing life-saving therapies.
Crimean-Congo hemorrhagic fever virus (CCHFV) is a dangerous virus spread by ticks. It causes Crimean-Congo hemorrhagic fever (CCHF), a serious disease that has been spreading into new regions of the world. Capable of killing up to 40% of those infected, it currently has no widely approved, highly effective treatments or vaccines.
Scientists led by Scott Pegan, a biomedical scientist at the University of California, Riverside, have now identified multiple targets for antibodies—proteins that protect us when an unwanted substance enters our body—that could one day help treat CCHF.
The researchers focused on a specific part of CCHFV called the nucleocapsid protein (NP), an internal viral protein that has traditionally received little attention as a therapeutic target. While the protein was previously used to detect the virus, the scientists realized that targeting it with antibodies can offer protection against CCHFV infection.
The researchers identified four areas on the NP to which antibodies can attach. The NP consists of a “head” and a “stalk” region. The study, published today in Nature Communications, found that antibodies can protect against the virus regardless of whether they attach to the head or the stalk.
In the mouse study, an antibody known as 9D5—the most powerful protective antibody—shielded the animals from lethal infection and showed potential to protect against different strains of the virus.
“This opens up new frontiers for what an antibody therapeutic for CCHF might look like,” said Pegan, a professor of biomedical sciences in the UCR School of Medicine.
Pegan and his colleagues used X-ray imaging to see exactly how 9D5 binds to the head region of the virus’s NP. Because the spot where the 9D5 antibody attaches is almost identical across different strains of the virus, it further highlights that 9D5, or antibodies like it, can protect against multiple versions of CCHFV.
Pegan explained that CCHFV is primarily spread by Hyalomma ticks and can also spread from person to person, particularly in health care settings. Infection can begin with nonspecific symptoms but often progresses to severe hemorrhagic disease and organ damage.
CCHFV is present in Eastern and Southern Europe, northwestern China, Central Asia, Africa, the Middle East, and the Indian subcontinent. The threat is also evolving, Pegan said. As environmental conditions change, the ticks that carry CCHFV have expanded into new areas, bringing the virus closer to densely populated regions.
“When I started working on CCHF, it wasn’t considered as high a priority,” Pegan said. “But in recent years, the environments where these ticks live have been changing. As those ticks spread into new regions, the disease can spread with them.”
Mobilizing the Immune System
The research builds on earlier work by Pegan and his team showing that antibodies directed at the virus’s NP can play an important role in protection. The 2024 study found that 9D5 protected mice from lethal CCHFV infection and recognized NPs from several virus strains.
The new finding is significant because the NP is not found on the outside of the virus, where antibodies typically target viral proteins. But the research indicates that the protein can appear on the surface of infected cells, creating an opportunity for antibodies to recognize and target it.
Rather than directly neutralizing the virus, these antibodies appear to work through a different immune mechanism. Recent research has pointed to a pathway that uses an intracellular protein, TRIM21, to provide a protective response.
“What’s interesting is that these are non-neutralizing antibodies,” Pegan said. “They’re not working in the same way as antibodies that bind to a viral surface protein and prevent the virus from entering a cell. Instead, they help mobilize the immune system to mount an effective response. It appears these NP-targeting antibodies may bind to an NP on the surface of the cell or a free-floating NP and are then taken inside the cell to interact with TRIM21. This enables the cells to present fragments of the NP to other immune cells that then can clear the infection.”
The researchers also discovered that 9D5 is not the only potentially protective antibody targeting the NP.
“We’ve shown that there are other sites that may have even greater potential for protective therapeutics,” Pegan said. “This discovery could be particularly important for developing antibody cocktails, in which multiple antibodies target different parts of the virus or infected cells.”
The next step for the team is to use the newly identified protective sites to find additional therapeutic antibodies, including those that offer strong protection against multiple CCHFV strains.
“We need to find out what makes an antibody protective, what qualities we should look for in an antibody that’s going to provide good protection and broad-spectrum activity,” Pegan said.
The current 9D5 antibody is a mouse antibody, meaning it is not itself expected to become a human treatment. Instead, the researchers hope the lessons learned from 9D5 will help them identify human or humanized antibodies suitable for further development.
“We’ve not only discovered where protective antibodies can bind,” Pegan said. “We’ve also discovered there are multiple opportunities for antibodies to bind to this antigen and provide protection. The result is a clear blueprint to design new antibody drugs and combination treatments that can broadly protect against CCHFV.”
Pegan estimates that an antibody treatment could potentially reach patients in about five years, depending on the success of preclinical research and clinical trials.
The approach, he said, could also have implications beyond CCHFV. Similar findings have emerged in research on other viruses, such as the Lassa virus, suggesting that NPs may represent a broader class of therapeutic targets.
“For decades, people have identified antibodies that bind to NPs, but most of that was for diagnostic purposes,” Pegan said. “It wasn’t really viewed as a viable therapeutic target. We now know that assumption was incorrect.”
Funding: The research was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, as well as the Military Infectious Disease Research Program.
Published in journal: Nature Communications
Authors: Vanessa Moresco, Aura R. Garrison, Clarissa A. Edmundo, Collin J. Fitzpatrick, Elif Karaaslan, Scott P. Olschner, Keersten M. Ricks, Oluwadara T. Ogundare, Laliv Tadri, Brian D. Carey, Mohammad M. Sajadi, Éric Bergeron, Joseph W. Golden, and Scott D. Pegan
Source/Credit: University of California, Riverside | Iqbal Pittalwala
Edited by: Scientific Frontline
Reference Number: vi082226_01